AU2001271266A1 - Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes - Google Patents

Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes

Info

Publication number
AU2001271266A1
AU2001271266A1 AU2001271266A AU7126601A AU2001271266A1 AU 2001271266 A1 AU2001271266 A1 AU 2001271266A1 AU 2001271266 A AU2001271266 A AU 2001271266A AU 7126601 A AU7126601 A AU 7126601A AU 2001271266 A1 AU2001271266 A1 AU 2001271266A1
Authority
AU
Australia
Prior art keywords
compositions
methods
degrading enzymes
induced inflammation
use against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271266A
Inventor
Gary J. Fisher
Sewon Kang
John J Voorhees
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Publication of AU2001271266A1 publication Critical patent/AU2001271266A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22—Peroxides; Oxygen; Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001271266A 2000-05-22 2001-05-22 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes Abandoned AU2001271266A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57659700A 2000-05-22 2000-05-22
US09/576,597 2000-05-22
US09/852,154 2001-05-09
US09/852,154 US20040235950A1 (en) 1999-05-20 2001-05-09 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
PCT/US2001/016537 WO2001089502A2 (en) 2000-05-22 2001-05-22 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes

Publications (1)

Publication Number Publication Date
AU2001271266A1 true AU2001271266A1 (en) 2001-12-03

Family

ID=27076996

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271266A Abandoned AU2001271266A1 (en) 2000-05-22 2001-05-22 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes

Country Status (7)

Country Link
US (2) US20040235950A1 (en)
EP (1) EP1284721A2 (en)
JP (1) JP2004515460A (en)
AU (1) AU2001271266A1 (en)
CA (1) CA2409929A1 (en)
MX (1) MXPA02011431A (en)
WO (1) WO2001089502A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050033251A1 (en) * 1998-12-08 2005-02-10 Quick-Med Technologies, Inc. Controlled release of biologically active substances from select substrates
DE10127432A1 (en) * 2001-06-06 2002-12-12 Beiersdorf Ag Cosmetic or dermatological preparations for combating undesirable skin pigmentation, containing synergistic combination of tyrosine-O-sulfate ester (or analog) and alpha-lipoic acid
US20100222316A1 (en) * 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2007077257A2 (en) * 2006-01-05 2007-07-12 Galderma Research & Development Acne lesions biomarkers and modulators thereof
US20080025930A1 (en) * 2006-07-31 2008-01-31 Hugo Corstjens Anti-aging Compositions Comprising Menyanthes Trifoliata Leaf Extracts and Methods of Use Thereof
WO2008034161A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
WO2008053199A1 (en) * 2006-10-30 2008-05-08 Astrazeneca Ab Combination therapy for the treatment of respiratory diseases
CN102014859B (en) 2008-04-22 2015-05-20 法国国家科学研究中心 Novel compositions which inhibit melanogenesis and uses thereof
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
EP2473845A4 (en) * 2009-09-02 2014-04-30 Univ Virginia Patent Found Tracking the probability for imminent hypoglycemia in diabetes from self-monitoring blood glucose (smbg) data
US8895628B2 (en) * 2010-10-25 2014-11-25 Johnson & Johnson Consumer Companies, Inc. Compositions comprising a retinoid and an NFkB-inhibitor and their methods of use
US20140086859A1 (en) 2012-09-24 2014-03-27 Johnson & Johnson Consumer Companies, Inc. Low oil compositions comprising a 4-substituted resorcinol and a high carbon chain ester
ES2604812T3 (en) * 2014-05-07 2017-03-09 Koninklijke Philips N.V. System and procedure for the extraction of physiological information
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
KR20200063798A (en) * 2018-11-28 2020-06-05 박정혜 A composition for improving acne of skin comprising quercetin, genistein and alpha-lipoic acid
WO2023068233A1 (en) * 2021-10-18 2023-04-27 マルホ株式会社 Activity inhibitor and/or production suppressant

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005198A (en) * 1975-09-12 1977-01-25 Robert H. Van Aman Treatment of acne vulgaris
US4219548A (en) * 1978-09-01 1980-08-26 The Procter & Gamble Company Topical anti-inflammatory composition
US4942031A (en) * 1988-02-23 1990-07-17 Levin Robert H Compositions containing LYCD and other topically active medicinal ingredients
LU87410A1 (en) * 1988-12-20 1990-07-10 Cird COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING POLYMERIC OR FATTY BODY MICROSPHERES CHARGED WITH AT LEAST ONE ACTIVE PRODUCT
WO1993010755A1 (en) * 1991-11-25 1993-06-10 Richardson-Vicks, Inc. Compositions for regulating skin wrinkles and/or skin atrophy
DE4218572A1 (en) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistic combination of drugs containing as active ingredient alpha-lipoic acid, dihydrolipoic acid, their metabolites as well as the oxidized and reduced enantiomers of alpha-lipoic acid such as R-alpha-lipoic acid or S-alpha-lipoic acid and metabolites of alpha-lipoic acid with vitamins A, B1 -6, B12, C and E
US5460620A (en) * 1992-07-31 1995-10-24 Creative Products Resource, Inc. Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent
FR2694934B1 (en) * 1992-08-24 1994-11-10 Oreal Composition for the treatment of acne containing a salicylic acid derivative and salicylic acid derivatives.
EP0692931A4 (en) * 1993-04-07 1996-03-20 Glycomed Inc Synthetic matrix metalloprotease inhibitors and uses thereof
FR2715565B1 (en) * 1994-01-31 1996-03-15 Oreal Stabilized cosmetic or dermatological composition containing several precursors of the same active ingredient to maximize its release, its use.
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
CA2194158C (en) * 1994-07-01 2000-08-22 Donald Lynn Bissett Desquamation compositions
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
DE4444238A1 (en) * 1994-12-13 1996-06-20 Beiersdorf Ag Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
US5643623A (en) * 1995-06-07 1997-07-01 Mars Incorporated Health food product and its uses
US6218128B1 (en) * 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
US5741896A (en) * 1996-06-21 1998-04-21 Allergan O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
DE19632840A1 (en) * 1996-08-14 1998-02-19 Landsberger Albert Composition containing vitamin A
US5665367A (en) * 1996-09-27 1997-09-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions containing naringenin and/or quercetin and a retinoid
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5962030A (en) * 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
TWI234467B (en) * 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
US6638949B1 (en) * 1997-08-25 2003-10-28 Judah Folkman Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Also Published As

Publication number Publication date
EP1284721A2 (en) 2003-02-26
US20060009494A1 (en) 2006-01-12
CA2409929A1 (en) 2001-11-29
JP2004515460A (en) 2004-05-27
WO2001089502A2 (en) 2001-11-29
MXPA02011431A (en) 2004-01-26
WO2001089502A3 (en) 2003-01-03
US20040235950A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2778801A (en) Antisense compositions and methods
AU2001249969A1 (en) Inha inhibitors and their use as antibacterials
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
AU2001294814A1 (en) Pumpcn compositions and uses thereof
AU2001294808A1 (en) Catecholamine pharmaceutical compositions and methods
AU2001280604A1 (en) Compositions comprising icariside i and anhydroicaritin and methods for making the same
AU2001233185A1 (en) Wound healing compositions and methods using tropoelastin and lysyl oxidase
AU2001234437A1 (en) Deicing compositions and methods of use
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU5326100A (en) Pharmaceutical compositions and methods for use
AU2001271266A1 (en) Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
AU2002230836A1 (en) Benzylamine derivatives and their use as thrombin inhibitors
AU2001248215A1 (en) Cosmetically active composition
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2001292047A1 (en) Composition containing an azaphthalocyanine and use
AU2002246655A1 (en) Compositions and methods for detecting proteolytic activity
AU2002213588A1 (en) Soluble cd1 compositions and uses thereof
AU2001233932A1 (en) Method and composition
AU2001269730A1 (en) Low carbohydrate compositions, kits thereof, and methods of use
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU4426801A (en) Composition based on sphingolipid and beta-hydroxy-acid for skin care
AU2002366809A1 (en) Syn3 compositions and methods